GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » ROC %

China Isotope & Radiation (HKSE:01763) ROC % : 9.94% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. China Isotope & Radiation's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was 9.94%.

As of today (2024-05-24), China Isotope & Radiation's WACC % is 7.88%. China Isotope & Radiation's ROC % is 9.34% (calculated using TTM income statement data). China Isotope & Radiation generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


China Isotope & Radiation ROC % Historical Data

The historical data trend for China Isotope & Radiation's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation ROC % Chart

China Isotope & Radiation Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only 17.43 12.00 10.65 10.64 10.65

China Isotope & Radiation Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.49 6.16 14.24 7.52 9.94

China Isotope & Radiation ROC % Calculation

China Isotope & Radiation's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=879.98 * ( 1 - 15.86% )/( (6260.062 + 7647.692)/ 2 )
=740.415172/6953.877
=10.65 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13165.757 - 3634.58 - ( 3271.115 - max(0, 4501.938 - 8424.321+3271.115))
=6260.062

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14428.814 - 3638.641 - ( 3142.481 - max(0, 4652.849 - 8962.937+3142.481))
=7647.692

China Isotope & Radiation's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=1010.5 * ( 1 - 13.88% )/( (9870.203 + 7647.692)/ 2 )
=870.2426/8758.9475
=9.94 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12903.126 - 653.447 - ( 2379.476 - max(0, 4440.945 - 8141.448+2379.476))
=9870.203

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14428.814 - 3638.641 - ( 3142.481 - max(0, 4652.849 - 8962.937+3142.481))
=7647.692

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Isotope & Radiation  (HKSE:01763) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, China Isotope & Radiation's WACC % is 7.88%. China Isotope & Radiation's ROC % is 9.34% (calculated using TTM income statement data). China Isotope & Radiation generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


China Isotope & Radiation ROC % Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


China Isotope & Radiation (HKSE:01763) Business Description

Traded in Other Exchanges
N/A
Address
No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Ubs Group Ag 2201 Interest of corporation controlled by you
Li Hongbo 2201 Interest of corporation controlled by you
Lianwen Ltd 2101 Beneficial owner
Invesco Advisers, Inc. 2102 Investment manager
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Invesco Hong Kong Limited 2102 Investment manager
Invesco Corporate Class Inc. 2106 Person having a security interest in shares
M&g Plc 2201 Interest of corporation controlled by you
Shanghai Industrial Holdings Limited 2201 Interest of corporation controlled by you
Shanghai Industrial Investment (holdings) Company Limited 2201 Interest of corporation controlled by you
Serenity Investment Master Fund Limited 2101 Beneficial owner
Serenity Capital Management, Ltd. 2102 Investment manager
Shanghai Pharmaceuticals Holding Co., Ltd. 2201 Interest of corporation controlled by you
S.i. Infrastructure Holdings Limited 2201 Interest of corporation controlled by you

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines